Ecubectedin (PM14) is an anticancer agent. Ecubectedin downregulates the expression of MDM2, thereby stabilizing and activating p53, it inhibits Bax/Bcl-2 and activates Caspase-3, ultimately inducing apoptosis. Ecubectedin exerts dual effects of direct killing and immunoregulation by inducing DNA damage, activating the innate immune signaling pathway (cGAS/STING) and triggering immunogenic cell death. Ecubectedin can be used in research related to human liver cancer and malignant pleural mesothelioma[1][2].
